Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Human respiratory syncytial virus (RSV) is a serious pediatric pathogen of the lower respiratory tract worldwide. There is currently no clinically approved vaccine against RSV infection. Recently, it has been shown that a replication-deficient first generation adenoviral vector (FGAd), which encodes modified RSV attachment glycoprotein (G), elicits long-term protective immunity against RSV infection in mice. The major problem in developing such a vaccine is that G protein lacks MHC-I-restricted epitopes. However, RSV fusion glycoprotein (F) is a major cytotoxic T-lymphocyte epitope in humans and mice, therefore, an FGAd-encoding F (FGAd-F) was constructed and evaluated for its potential as an RSV vaccine in a murine model. Intranasal (i.n.) immunization with FGAd-F generated serum IgG, bronchoalveolar lavage secretory IgA, and RSV-specific CD8+ T-cell responses in BALB/c mice, with characteristic balanced or mixed Th1/Th2 CD4+ T-cell responses. Serum IgG was significantly elevated after boosting with i.n. FGAd-F. Upon challenge, i.n. immunization with FGAd-F displayed an effective protective role against RSV infection. These results demonstrate FGAd-F is able to induce effective protective immunity and is a promising vaccine regimen against RSV infection.
Fu
Yuanhui
Y
Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
He
Jinsheng
J
Zheng
Xianxian
X
Wu
Qiang
Q
Zhang
Mei
M
Wang
Xiaobo
X
Wang
Yan
Y
Xie
Can
C
Tang
Qian
Q
Wei
Wei
W
Wang
Min
M
Song
Jingdong
J
Qu
Jianguo
J
Zhang
Ying
Y
Wang
Xin
X
Hong
Tao
T
D000256:Adenoviridae / Q000235:genetics / Q000502:physiology; D000281:Administration, Intranasal; D000818:Animals; D000917:Antibody Formation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D008168:Lung / Q000276:immunology / Q000473:pathology / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D018357:Respiratory Syncytial Virus Infections / Q000473:pathology / Q000517:prevention & control*; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D014611:Vaccination; D014760:Viral Fusion Proteins / Q000235:genetics / Q000276:immunology*; D014779:Virus Replication / Q000235:genetics
D022261:Respiratory Syncytial Virus Vaccines; D014760:Viral Fusion Proteins